How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma TreatmentVideo Categories: 2018 ASCO Insights and Video Library
Dr Sanjiv Agarwala reviews real-world data presented at ASCO 2018 on immunotherapy of melanoma that serve to reassure providers regarding current treatment approaches, but do not offer any significant practice-changing results.
Dr. Mesa recognizes that although genotypic data is not yet being used to select treatment choice or dosing in myelofibrosis, it is used to address the issues of prognosis and burden of disease.
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of antiâ€“PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of antiâ€“PD-1 over antiâ€“CTLA-4, and new results in combining immunotherapies.